Introduction
In normal prostate, bcl-2 expression is restricted to the basal cells of the glandular epithelium which are resistant to the eects of androgen deprivation (Hockenbery et al., 1991) . In contrast, the bcl-2 negative secretory epithelial cells undergo apoptotic cell death in response to androgen deprivation (English et al., 1987) . Therefore, the secretory cells of the prostatic glandular epithelium require testosterone to remain viable and proliferate. Additionally, the deregulated expression of the bcl-2 proto-oncogene has been implicated in the pathogenesis and progression of prostate cancer (Bruckheimer et al., 1999) .
Bcl-2 is a member of a multigene family consisting of interacting pro-survival and pro-apoptotic family members. The rheostat model suggests that the susceptibility of a cell to undergo apoptosis is determined by the balance of pro-survival and proapoptotic members of this gene family . Bax, a member of the bcl-2 gene family, has been shown to function as a dominant acting cell death eector protein . In the normal prostate, bax expression is observed in both the secretory and basal epithelial cells of the prostate with increased expression observed in the secretory epithelial cells, which are more susceptible to apoptosis resulting from androgen-deprivation (Krajewska et al., 1996) . Interestingly, the upregulation of bax expression has been shown to correlate temporally with apoptosis induction in xenografts of the androgen-sensitive LNCaP cell line following castration (Beham et al., 1998) .
Recently, our ability to assess the impact of individual gene products in the prostate has been greatly facilitated by the characterization of gene promoters that enable targetting to the prostate (Greenberg et al., 1994; Maroulakou et al., 1994; Pang et al., 1997; Cleutjens et al., 1997; Zhang et al., 1997) . The most extensively studied transgenic model involves the targeting of transgene expression using the probasin promoter (Greenberg et al., 1995; Gingrich et al., 1996 Gingrich et al., , 1997 . We used the probasin promoter to target expression of a human bcl-2 transgene speci®-cally to the prostate in order to assess its impact on conferring resistance to androgen withdrawal in prostatic glandular epithelial cells in vivo. Additionally, we examined the contribution of bax to mediating androgen-responsiveness in prostatic glandular epithelial cells using bax knockout mice (Knudson et al., 1995) .
Results

Generation of probasin-bcl-2 transgenic mice
The probasin promoter was used to generate a transgene construct containing the human bcl-2 cDNA (Figure 1 ). Southern blot analysis using a 32 P-labeled probe speci®c for exon 2 of human bcl-2 demonstrated the presence of the transgene in the tail DNA of four founder mice (Figure 2 ).
Tissue specificity of probasin-bcl-2 transgene expression
In order to establish the speci®c targeting of bcl-2 transgene expression in the prostate, Western blot analysis was performed on protein lysates obtained from 15 dierent organs from both WT and bcl-2 mice at 10 weeks of age. Human bcl-2 expression was limited to the ventral and dorsolateral lobes of the prostate with 1.8-fold lower expression observed in the dorsolateral prostate when compared to the ventral prostate (Figure 3 ). Human bcl-2 was undetectable in the seminal vesicles, vas deferens, testes, urinary bladder, brain, heart, liver, kidney, thymus, spleen or skeletal muscle. The cytoarchitectural distribution of transgenic bcl-2 expression within the prostate of 6-week-old mice was evaluated using immunohistochemical techniques and a human speci®c anti-bcl-2 monoclonal antibody. Both secretory and basal glandular epithelial cells of the bcl-2 transgenic mice displayed positive staining for human bcl-2 (Figure 4) . No positive staining for human bcl-2 was observed in stromal cells. Additionally, immunoblot analysis demonstrated that prostates of bcl-2 transgenic mice exhibit an approximately twofold increase in transgenic bcl-2 protein compared to endogenous bcl-2 levels in control littermate mice (not shown).
Morphology of the prostate in the probasin bcl-2 transgenic mouse
Prostates from adult control littermate and probasinbcl-2 transgenic mice up to 7 months of age were examined without knowledge of genotype using light microscopy. Consistent dierences in either the prostatic glandular epithelium or stromal elements between bcl-2 transgenic and control littermate mice were not observed. Wet weight determinations also revealed no signi®cant dierences between bcl-2 transgenic and control littermate mice in the size of the ventral and dorsolateral lobes of the prostate. At 12 weeks of age the mean wet weight of the ventral prostate was 9.91+0.65 mg and 9.94+0.65 mg in control littermate and bcl-2 transgenic mice, respectively. The mean weight wet of the dorsal prostate was 9.92+0.80 mg and 8.26+0.54 mg for control littermate and bcl-2 transgenic mice, respectively. Figure 1 Diagram of the probasin-Bcl-2 construct. The construct consisted of a probasin promoter region 7426 to +28 (cross-hatched) inserted upstream of a human bcl-2 cDNA (stippled). An SV40 splice and polyadenylation signal (shaded) were added to optimize transgene expression Figure 2 Southern blot analysis of founder tail DNA. The presence of the probasin-bcl-2 construct in founder lines 3558, 4751, 4758 and 4483 was determined by Southern blot analysis using a radio-labeled probe speci®c for exon 2 of human bcl-2. The positive control is a plasmid vector possessing a human bcl-2 cDNA insert (pBK2). The negative control is murine genomic DNA Figure 4 Histologic distribution of trangenic Bcl-2 protein in the ventral prostate. The distribution of transgenic bcl-2 protein in the ventral prostates of control littermate (upper panel) and probasin-bcl-2 (lower panel) mice at 6 weeks of age using a monoclonal antibody speci®c for human bcl-2. Transgenic bcl-2 protein was localized to the prostatic glandular epithelium. No detectable transgenic bcl-2 protein was observed in the stromal elements. There was no detectable cross-reactivity with endogenous bcl-2 in prostates from control littermate mice. 3006 magni®cation Steady-state levels of apoptosis in bcl-2 transgenic and control littermate mice were not signi®cantly dierent. A mean apoptotic index of 0.57+0.17% for the ventral and 0.35+0.1% for the dorsal lobes of the prostate was observed in the bcl-2 transgenic mice compared to 0.50+0.11 and 0.49+0.9% in the ventral and dorsal lobes, respectively, of control littermate mice.
In order to quantitate rates of proliferation in control littermate and bcl-2 transgenic mice, 8-weekold animals were given intraperitoneal injections of BrdU and subsequently the prostates were examined immunohistochemically for the extent of BrdU incorporation. The proliferative indices for the ventral prostates of control littermate and bcl-2 transgenic mice were 0.20+0.07 and 0.32+0.4%, respectively, and were not signi®cantly dierent. Similarly, the proliferative indices of dorsal prostates of 0.23+0.04 and 0.22+0.10% for control littermate and bcl-2 transgenic mice, respectively, were not signi®cantly dierent.
Probasin-bcl-2 protects against apoptosis induction in prostatic glandular epithelial cells following androgen-ablation Mice 8 weeks of age were castrated and the ventral and dorsolateral lobes of the prostate harvested 1, 3, 5, 7, 10 and 14 days following castration. The TUNEL technique was used to label cells containing fragmented DNA consistent with apoptosis ( Figure 5 ). Prostate glandular epithelial cell apoptosis was quantitated by scoring TUNEL positive cells as described in the Materials and methods (Figure 6a,b) . The apoptotic index in the ventral prostates of control littermate mice reached a maximum of 2.68+0.36% 5 days after castration and was signi®cantly greater than the apoptotic index of 1.28+0.25% in the ventral prostates of bcl-2 transgenic mice (P40.008) (Figure 6a ). The apoptotic index in the ventral prostates of bcl-2 mice did not increase modestly, with a peak value of 1.40+0.31% observed 7 days after castration.
Compared to the ventral prostate, apoptosis induction in the dorsolateral prostate was relatively modest and delayed in onset. The peak apoptotic index of 1.32+0.33% was observed on day 14 after castration, representing an approximately twofold increase over precastrate levels ( Figure 6a ). The peak apoptotic index in the dorsolateral lobe of the prostate in bcl-2 transgenic mice, 0.79+0.10% was also observed on day 14 and also represented an approximately twofold increase over precastrate levels. The dierence between apoptotic indices in the dorsolateral lobes of the prostate from control littermate and bcl-2 transgenic mice following castration did not achieve statistical signi®cance (P=0.08).
Apoptosis induction in the prostate of bax 7/7 mice following androgen-ablation Precastrate levels of apoptosis in the ventral and dorsolateral lobes of the prostate from 8-week-old bax 7/7 mice were 0.39+0.08 and 0.41+0.09%, respectively ( Figure 6b ). The kinetics of apoptosis induction in the ventral lobe of the bax 7/7 mice diered from that of control littermate mice. An apoptotic index of 1.28+0.39% was observed on day 5 post-castration in the bax 7/7 mice, signi®cantly less than (P40.03) that of control littermate mice ( Figure 6b ). Peak levels of apoptosis in the ventral prostate of bax 7/7 mice were observed on day 14 post-castration with an apoptotic index of 2.04+0.39%. Interestingly, this was signi®-cantly more than (P40.05) that observed for control littermate mice (Figure 6b ).
The apoptotic indices of the ventral lobe for bax
mice at days 1 and 14 following castration were 
Modulation of bcl-2 and bax expression in the prostate following androgen-ablation
Densitometric scans of immunoblots were used to evaluate variation in bcl-2 and bax expression in the prostate following castration. Data were normalized using actin as a load control to ensure valid comparisons. A time course Western blot analysis of human bcl-2 protein in the prostate following castration was undertaken to assess the extent of transgene downregulation due to use of the androgen-regulated probasin promoter element (Figure 7 ). Precastrate levels of human bcl-2 protein were maintained in the ventral prostate until day 7 postcastration. Transgenic bcl-2 expression decreased sevenfold on day 7 following castration in the ventral prostate. A more rapid reduction in human bcl-2 was observed in the dorsolateral prostate where a 16-fold reduction occurred by day 3 following castration ( Figure 7b ).
Therefore, the signi®cant reduction in apoptotic index observed in the ventral prostates of bcl-2 transgenic mice compared to that of control littermates on day 5 following castration was associated with precastrate levels of transgenic bcl-2 protein.
The modulation of endogenous murine bcl-2 and bax protein in the ventral and dorsolateral prostates of control littermate (Figure 7a ), probasin-bcl-2 transgenic ( Figure 7b ) and bax 7/7 (Figure 7c) mice were also examined. In the ventral prostates of control littermate mice, endogenous bcl-2 levels increased sixfold at day 5, declined to precastrate levels on day 7, then increased 10-fold on days 10 and 14 following castration (Figure 7a) . Changes in the level of bax protein correlated temporally with that of bcl-2 in the ventral prostates of control mice following castration (Figure 7a ). In the dorsolateral prostate of control mice, endogenous murine bcl-2 and bax proteins increased 5.7 and 1.2-fold, respectively, on day 7 following castration ( Figure 7a ). Endogenous bcl-2 protein in the dorsolateral prostates of control mice remained elevated approximately threefold above precastrate levels 14 days after castration (Figure 7a ).
The ventral prostates of bcl-2 transgenic mice exhibited a 2.2-fold increase in endogenous murine bcl-2 at day 5 following castration ( Figure 7b ). The level of endogenous bcl-2 then normalized to approximately precastrate levels by day 14 post-castration. Bax levels increased slightly, 1.3-fold, in the ventral prostates of bcl-2 transgenic mice increased and, similar to endogenous bcl-2, normalized by day 14 (Figure 7b ). The dorsolateral prostates of bcl-2 transgenic mice showed no detectable increase in either endogenous bcl-2 or bax following castration ( Figure  7b ). In fact levels of both endogenous bcl-2 and bax exhibited a reduction relative to precastrate levels of these proteins on days 1 and 14 following castration.
As expected, bax protein levels were undetectable by immunoblotting in the prostates of bax 7/7 mice (not shown). An increase in endogenous bcl-2 of 1.2-fold in the ventral prostate and 1.4-fold in the dorsolateral lobe of the prostate three were observed on days 5 and 3, respectively, following castration (Figure 7c) . In both the ventral and dorsolateral prostate the level of bcl-2 protein approximated precastrate levels by day 14 following castration.
Discussion
Previous immunohistochemical studies of human prostate tissue have demonstrated the expression of the anti-apoptotic bcl-2 proto-oncogene. Typically, bcl-2 expression is limited to the basal cells of the prostatic glandular epithelium (Hockenbery et al., 1991; McDonnell et al., 1992) . Deregulated expression of bcl-2 has been correlated with both prostate neoplasia and the progression of prostate carcinoma (McDonnell et al., 1992; Colombel et al., 1993) . The ability to assess the molecular regulation of homeostatic cell numbers in the prostate in vivo has been greatly facilitated by the use of gene promoter elements to enable targetted gene expression. The rat probasin gene promoter has been demonstrated to be of particular utility in this context (Greenberg et al., 1994 (Greenberg et al., , 1995 . Using the probasin gene promoter we were able to target expression of a human bcl-2 transgene speci®cally to the prostatic glandular epithelium. Detectable levels of transgene expression in other tissues, including seminal vesicles, urinary bladder, and testes were not observed. The potential limitations of low levels of transgene expression and lack of tissue speci®city observed with other gene promoters used to target the prostate gland, such as C3(1) and prostate speci®c antigen, appear to be signi®cantly minimized by use of the probasin promoter element (Maroulakou et al., 1994; Zhang et al., 1997) .
The histologic appearance of the prostates from probasin-bcl-2 transgenic mice did not dier from those of control littermates. Additionally, there was no evidence of hyperplastic or neoplastic growth in transgenic mice up to 1 year of age. The absence of prostatic hyperplasia in the probasin-bcl2 mice is a clearly dierent consequence of enforced bcl-2 expression in other cells types in transgenic models. For example enforced expression of bcl-2 in B lymphocytes in bcl-2-immunoglobulin transgenic mice results initially in a 3 ± 4-fold expansion in the number of B lymphocytes and lymphoid hyperplasia (McDonnell et al., 1989) . The number of neurons in the central nervous systems of mice was signi®cantly increased when bcl-2 expression was enforced using the neuronspeci®c enolase promoter (Martinou et al., 1994) . These hyperplasias are considered to result from bcl-2's ability to inhibit what has been referred to as naturally occurring' cell death. Terminally dierentiated B lymphocytes, if they do not encounter cognate antigen, die in a matter of days or weeks. Naturally occurring cell death is also a characteristic feature of the developing nervous system in which the number of neurons initially generated vastly exceeds their functional requirements. Neurons which do not establish appropriate functional connections are then deleted. In contrast to these systems, transgene expression using the probasin promoter element is delayed until the onset of sexual maturation at approximately 2 ± 7 weeks, postnatally (Greenberg et al., 1994) . Additionally, the average life span of a human prostatic glandular epithelial has been estimated to be in excess of 2 years (Tunn et al., 1989) . It is, therefore, reasonable to speculate that the absence of any demonstrable prostatic hyperplasia in the bcl-2 probasin transgenic mice is attributable to the delayed onset of transgene expression and the slow turnover of prostatic glandular epithelial cells. The lack of demonstrable dierences between probasin bcl-2 transgenic mice and control littermates in steady-state levels of apoptosis or proliferation would support this contention.
The C3(1) gene promoter has also been used to target bcl-2 expression to the prostate (Zhang et al., 1997) . Expression of transgenic bcl-2 was con®rmed in the prostate and other tissues. Although there was no apparent dierence in the size or apparent wet weights of the prostate glands, an accumulation of luminal and stromal cells was observed in prostates of approximately 20 ± 50% of the C3(1)-bcl-2 transgenic mice. The basis for the dierence in phenotype between the probasin and C3(1)-bcl-2 transgenic mice is not known. It is possible that there are developmental dierences in the C3(1) and probasin promoter activity. The fact that an increase in prostate cell number was not uniformly observed in all C3(1)-bcl-2 mice suggests the possibility that secondary events are required for this phenotype. The accumulation of stromal cells observed in the prostates of C3(1)-bcl-2 transgenic mice is presumed to be indirect in that bcl-2 expression was not observed in stromal cells. No data was provided regarding steadystate levels of proliferation or apoptosis for the C3(1)-bcl-2 transgenic mouse model (Zhang et al., 1997) .
Bcl-2 was shown to provide signi®cant protection against cell death induction resulting from androgen ablation in the ventral prostate of probasin bcl-2 transgenic mice (P40.008). This observation extends the results from previous in vitro and in xenograft models where increased levels of bcl-2 suppressed apoptosis in androgen-sensitive prostate cancer cells following androgen withdrawal or castration (Rao et al., 1995; Westin et al., 1997; Beham et al., 1998) . The probasin-bcl-2 transgenic mouse convincingly demonstrates that bcl-2 suppresses apoptosis induction following hormone ablation in vivo in non-neoplastic prostatic glandular epithelial cells. The modest increase in apoptotic indices observed in the ventral prostate observed 5 ± 7 days following castration may be attributable to the downregulation of transgene expression.
Apoptosis induction following castration in the dorsolateral lobes of the prostates from wild-type, bcl-2, and bax 7/7 mice was in general less than that of the ventral prostate at all time points examined. These ®ndings are consistent with previous observations of the relative androgen insensitivity of rodent dorsolateral prostate (Banerjee et al., 1995) . No signi®cant dierence in apoptotic indices between the dierent genotypes in the dorsolateral prostate was observed.
An important determinant of cell death susceptibility is the relative amount of bcl-2 and bax . Although the contribution of bax to the mediation of androgen-sensitivity in prostate cancer cells has not been established several observations support this possibility. We have recently shown that the induction of bax in xenografts of the androgensensitive prostate cancer cell line, LNCaP, corresponds temporally to apoptosis induction following castration (Beham et al., 1998) . Additionally, we have previously demonstrated that bax protein is also induced in the rodent ventral prostate following castration and again corresponds, temporally, with apoptosis induction (Westin et al., 1997) . These observations have recently been con®rmed (Perlman et al., 1999) . Conversely, the androgen-sensitive Dunning G prostate carcinoma cell line does not exhibit an increase in either the rate of apoptosis or bax protein following castration (Westin et al., 1997) . These observations suggest that bax, or alterations in the bax/bcl-2 ratio, may modulate apoptosis induction within the prostate following hormone ablation.
If bax, in fact, is a determinant of androgensensitivity then it might be anticipated that a loss of bax activity would result in a decrease in cell death susceptibility following androgen ablation. In this study male bax knock-out mice were used to determine whether bax is required for the mediation of androgensensitivity in prostatic glandular epithelial cells. The apoptotic index of the ventral prostate in bax 7/7 mice was signi®cantly less than that of control littermates on day 5 following castration (P40.03). In general, the apoptotic index of the ventral prostate in bax 7/7 mice was comparable to or exceeded that of control littermates. The apoptotic index was signi®cantly higher in ventral prostate in bax 7/7 mice, compared to control littermates, 14 days after castration (P40.05). Additionally, the apoptotic index in the ventral prostate of the bax 7/7 mice was signi®cantly higher than that observed in the ventral prostate of bcl-2 transgenic mice on days 1 and 14 following castration. Overall, this study suggests that both bax and bcl-2 may each contribute to the sensitivity of prostatic glandular epithelial cells to cell death induction following castration. It should be emphasized, however, that the regulation of apoptosis in prostatic glandular epithelial cells is complex. It is acknowledged, therefore, that mediators of androgenresistance and androgen-sensitivity other than bcl-2 and bax, respectively, likely exist. Recent evidence of modulations of clusterin (TRPM-2) and par-4 expression are of particular interest in this context (Lakins et al., 1998; Boghaert et al., 1997) .
It is apparent from these results, however, that bax is not absolutely required to mediate cell death in androgen-sensitivity prostatic glandular epithelial cells following castration. A comparison between the apoptotic indices in the ventral prostate in the probasin-bcl-2 and bax 7/7 mice following castration suggests that the presence of bcl-2 may be a more important indicator of androgen-sensitivity than the absence of bax. Similar ®ndings have recently been reported suggesting that bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo (Schorr et al., 1999) . It was, therefore, of interest to examine the relationship between these two key apoptotic regulatory proteins in the prostate following castration.
Immunoblotting techniques were used to assess modulations in the level of endogenous bcl-2 and bax proteins in the ventral and dorsolateral prostates from control littermate, probasin-bcl-2 transgenic, and bax 7/7 mice following castration. In general, modulations in the amounts of bcl-2 and bax proteins occurred coordinately in control littermate and bcl-2 transgenic mice. The peak in bax protein was observed on day 5 following castration and coincided with the peak in apoptotic index in control littermate mice. A sixfold increase in the amount of bcl-2 protein was also observed on day 5 post-castration. Additionally, the level of bcl-2 protein exhibited a sustained increase in the ventral prostates of control littermate mice whereas bax protein tended to return to precastrate levels within 14 days.
These ®ndings do not precisely correspond to those reported for the rat ventral prostate and to some extent this may re¯ect inherent species speci®c dierences (Perlman et al., 1999) . Our data suggest that apoptosis resulting from androgen deprivation in the murine ventral prostate may not simply be attributable to alterations in the bax/bcl-2 ratio. It is possible that pro-apoptotic molecules other than bax may be more critical in mediating sensitivity to androgen withdrawal in this context. Alternatively, it is conceivable that both an increase in the absolute amount of bax and its appropriate subcellular distribution are necessary to mediate androgen sensitivity (Gross et al., 1999) .
Materials and methods
Construction of the bcl-2 transgene
The probasin-bcl-2 transgene was constructed by ligating a human bcl-2 cDNA possessing the complete open reading frame into pBluescript SK 7 downstream of a 7426 to +28 rat probasin promoter fragment. SV40 sequences provided terminal RNA splicing and polyadenylation signals. The probasin-bcl-2 construct was linearized prior to microinjection.
Production and screening of transgenic mice
The generation of the transgenic mice, tail DNA isolation and PCR screening were described previously (Greenberg et al., 1994) . The sequences for the PCR primers used for the probasin-bcl-2 transgenic mice were the following (5' to 3'): PB1-28, CTTGTCAGTGAGGTCCAGATACCTACAG; Bcl-2 reverse, CCTCTGCGACAGCTTATAATGGATGTAC. The bcl-2 transgenic mice were generated in a FVB background and crossed into C57BL/6 mice. The heterozygous males from the F1 generation were used in all studies. Control mice (WT) used were non-transgenic littermates. The presence of the probasin bcl-2 transgene was determined by Southern blot analysis using DNA generated from the PCR ampli®cation of founder tail DNA separated on 1% agarose gel and transferred to nitrocellulose. The blot was then probed with a 32 P-labeled DNA probe for exon 2 of human bcl-2 and visualized by autoradiography.
The bax 7/7 knockout mice (Knudson et al., 1995) were generously provided by Dr Stanley Korsmeyer (Harvard Medical School, Boston, MA, USA) and the genotypes determined by PCR screening with oligonucleotides speci®c for the bax construct as described (Knudson and Korsmeyer, 1997) .
Western blot analysis
Ventral and dorsolateral prostates were homogenized through an 18 gauge needle (50 strokes) in Triton X100 (TX100) lysis buer (15 mM NaCl, 25 mM Tris pH 7.4, 1% TX100, 100 mM sodium orthovanadate, 1 mM PMSF, and 2 mg/mL aprotonin). Other tissues were harvested and homogenized in TX100 buer using the Brinkman Polytron Tissue Homogenizer. Protein content was assayed using the Biorad protein assay (Biorad, Hercules, CA, USA). Aliquots of protein (60 mg) were loaded on 7/14% SDS stacked polyacrylamide gels. After electrophoresis, proteins were electrotransferred to nitrocellulose membrane. Membranes were blocked with 5% dry milk in PBS-T (phosphate buered saline containing 0.05% Tween 20) for 1 h at room temperature then incubated with the primary antibody overnight at 48C. Primary antibodies included those for human bcl-2 (hamster monoclonal Pharmingen 6C8 #15131A, 1 : 1000 dilution), murine bcl-2 (hamster monoclonal Pharmingen 3F11 #15021A, 1 : 1000 dilution), bax (rabbit polyclonal Santa Cruz #sc-493, 1 : 500), and bcl-x L (rabbit polyclonal Santa Cruz #sc-634, 1 : 500 dilution) proteins. Additionally, anti-actin antibodies (Sigma) were used to evaluate protein loading and to enable normalization of expression levels. Following incubation with primary antibody, the membranes were washed and incubated with species speci®c horse-radish peroxidase labeled secondary antibodies for 1 h at room temperature (goat anti-hamster HRP antibody Jackson ImmunoResearch #107-035-142, 1 : 1000 dilution, sheep anti-mouse HRP Amersham #NA 931, 1 : 1000 dilution or donkey anti-rabbit HRP Amersham #NA 934, 1 : 1000 dilution). Membranes were subsequently incubated with the enhanced chemiluminescence system (ECL, Amersham Life Sciences) for 1 min and autoradiographed using X-ray ®lm (Amersham).
Immunohistochemical analyses
Ventral and dorsolateral prostates were ®xed overnight in 10% phosphate-buered-formalin and then routinely processed for paran embedment. Prostate tissue was also snap frozen in OCT and stored at 7808C until sectioning. All sections were stained with H&E and the histology reviewed by light microscopy. The presence of human bcl-2 was determined on frozen sections using the following protocol. Sections were ®xed in cold acetone for 10 min, washed, treated with 0.1% H 2 O 2 in methanol for 10 min, washed, and blocked in 10% goat serum in PBS for 30 min. Sections were incubated with primary anti-human bcl-2 antibody (hamster monoclonal Pharmingen 6C8 #15131A, 1 : 50 dilution) for 1 h followed by incubation with secondary antibody (goat antihamster HRP antibody Jackson ImmunoResearch #107-035-142, 1 : 200 dilution) for 45 min, and detected with Vectastain ABC kit (PK4000, Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin.
Animal surgery
Hormone ablation was achieved by surgical castration of 8-week-old male mice. Brie¯y, animals were anesthetized with metophane, a lateral incision was made into the scrotum and the testes ligated and removed. The incision was closed with surgical silk.
Apoptosis detection by TUNEL staining
The ventral and dorsolateral prostates were harvested from 8-week-old WT, bcl-2 and bax knockout mice. The tissue was ®xed overnight in 10% phosphate-buered-formalin, and then subjected to standard tissue processing. TUNEL staining was performed according to established procedures (Gavrieli et al., 1992) . Brie¯y, tissue sections were deparanized in xylene then rehydrated in ethanol. The sections were then incubated with proteinase K (0.02 mg/ml) for 15 min at 318C. Endogenous peroxidases were removed by incubation with 2% H 2 O 2 for 5 min at room temperature. The labeling reaction occurred for 1 h at 378C using UTP (1 : 200 dilution) and TdT (1 : 400 dilution) in the presence of Mn
2+
. Incubation with strepavidin-horseradish peroxidase for 45 min followed by incubation with AEC for 15 min enabled detection of cells that incorporated dUTP. Sections were counterstained with hematoxylin. Positive controls consisted of a tissue section incubated 10 mg/ml DNase prior to proteinase K treatment. Apoptosis was quantitated by scoring 500 epithelial cells per ®eld in ®ve random ®elds per tissue section.
BrdU incorporation and immunohistochemistry
WT and bcl-2 mice, at 8 weeks of age, were injected intraperitoneally, with 5.5 mg/100 g body weight BrdU (Sigma #B0631). A second injection was performed 2 h after the ®rst and the ventral and dorsolateral prostates were harvested 2 h after the second injection. Tissues were ®xed overnight in 70% cold EtOH, dehydrated in 100% EtOH, placed in xylene for 24 h followed by paran embedding. Immunohistochemical detection of cells that incorporated BrdU was performed by deparanizing tissues, treating with 2N HCl, treating and blocking with 1% goat serum in 30% Methanol+0.3% H 2 O 2 . Sections were incubated with primary anti-BrdU antibody (mouse monoclonal Becton Dickinson #347580, 1 : 50 dilution) for 1 h followed by incubation with secondary antibody (sheep anti-mouse HRP Amersham #NA 931, 1 : 100 dilution) for 1 h. Cells incorporating BrdU were visualized using the Vectastain ABC kit (PK4000, Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin. Proliferation was quantitated by scoring 500 epithelial cells per ®eld in ®ve random ®elds per tissue section.
Statistical analyses
Paired T-tests were used to assess the apoptosis induction and basal apoptosis with a con®dence value of 95%. The Mann ± Whitney/Wilcoxon rank sum test was performed on the BrdU incorporation/proliferation data. For wet weight determinations, the Mann ± Whitney/Wilcoxon rank sum test was also performed.
